Livostin Augndropar, dreifa 0,5 mg/ml Iceland - Iceland - LYFJASTOFNUN (Icelandic Medicines Agency)

livostin augndropar, dreifa 0,5 mg/ml

mcneil sweden ab - levocabastinum hýdróklóríð - augndropar, dreifa - 0,5 mg/ml

Optovite B12 Stungulyf, lausn 1000 míkróg Iceland - Iceland - LYFJASTOFNUN (Icelandic Medicines Agency)

optovite b12 stungulyf, lausn 1000 míkróg

laboratorios normon s.a. - cyanocobalaminum inn - stungulyf, lausn - 1000 míkróg

Hydroxyzine Medical Valley Filmuhúðuð tafla 25 mg Iceland - Iceland - LYFJASTOFNUN (Icelandic Medicines Agency)

hydroxyzine medical valley filmuhúðuð tafla 25 mg

medical valley invest ab - hydroxyzinum hýdróklóríð - filmuhúðuð tafla - 25 mg

Dymista Nefúði, dreifa 137 míkróg / 50 míkróg/skammt Iceland - Iceland - LYFJASTOFNUN (Icelandic Medicines Agency)

dymista nefúði, dreifa 137 míkróg / 50 míkróg/skammt

viatris aps - azelastinum hýdróklóríð; fluticasonum própíónat - nefúði, dreifa - 137 míkróg / 50 míkróg/skammt

Sandomigrin Húðuð tafla 0,5 mg Iceland - Iceland - LYFJASTOFNUN (Icelandic Medicines Agency)

sandomigrin húðuð tafla 0,5 mg

ethyx pharmaceuticals - pizotifenum maleat - húðuð tafla - 0,5 mg

Darzalex Kesatuan Eropah - Iceland - EMA (European Medicines Agency)

darzalex

janssen-cilag international n.v. - daratumumab - mergæxli - monoclonal antibodies and antibody drug conjugates, antineoplastic agents - multiple myelomadarzalex is indicated: in combination with lenalidomide and dexamethasone or with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. ásamt bortezomib, dauða og leiðbeina fyrir meðferð fullorðinn sjúklinga með nýlega greind margar forráðamenn sem eru rétt fyrir samgena stafa klefi grætt. ásamt lenalídómíði og leiðbeina, eða bortezomib og leiðbeina, fyrir meðferð fullorðinn sjúklinga með mörgum forráðamenn sem hafa fengið að minnsta kosti einn áður en meðferð. in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one prior therapy containing a proteasome inhibitor and lenalidomide and were lenalidomide refractory, or who have received at least two prior therapies that included lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or after the last therapy (see section 5. eitt og sér fyrir meðferð fullorðinn sjúklinga með fallið og svarar margar forráðamenn, sem áður en meðferð fylgir proteasome hemil og virkt efni og sem hafa sýnt sjúkdóms á síðustu meðferð. al amyloidosisdarzalex is indicated in combination with cyclophosphamide, bortezomib and dexamethasone for the treatment of adult patients with newly diagnosed systemic light chain (al) amyloidosis.

Anafranil Húðuð tafla 25 mg Iceland - Iceland - LYFJASTOFNUN (Icelandic Medicines Agency)

anafranil húðuð tafla 25 mg

pharmaand gmbh - clomipraminum hýdróklóríð - húðuð tafla - 25 mg

Ismo Forðatafla 60 mg Iceland - Iceland - LYFJASTOFNUN (Icelandic Medicines Agency)

ismo forðatafla 60 mg

teva b.v.* - isosorbidi mononitras inn - forðatafla - 60 mg

Metoprololsuccinat Hexal Forðatafla 100 mg Iceland - Iceland - LYFJASTOFNUN (Icelandic Medicines Agency)

metoprololsuccinat hexal forðatafla 100 mg

hexal a/s - metoprololum súkkínat - forðatafla - 100 mg

Metoprololsuccinat Hexal Forðatafla 25 mg Iceland - Iceland - LYFJASTOFNUN (Icelandic Medicines Agency)

metoprololsuccinat hexal forðatafla 25 mg

hexal a/s - metoprololum súkkínat - forðatafla - 25 mg